ClinicalTrials.gg
TerminatedNCT01507233IMPROVE-OpenUpdated Mar 6, 2014Results posted

A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302

A Phase 4 interventional study of IV morphine sulfate and EXPAREL (bupivacaine liposome injectable suspension) in Bowel Obstruction, sponsored by Pacira Pharmaceuticals, Inc. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-06.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 4, Interventional, and Health services research

Why this study was terminated
Slow enrollment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
5
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Intestinal Obstruction with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Intestinal Obstruction · United States.

Enrollment
13th of 16
5 · median 59
Started
2012
with 1 other
Phase 4
5 of 29
none open now
Registered
9th of 29
by date
Lead sponsor
4 of 29
Pacira Pharmaceuticals, Inc

Among the 29 studies in Intestinal Obstruction with a site in United States, this one is the 13th largest by enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2012, is one of 5 in phase 4, and was the 9th registered.

Intestinal Obstruction

105 studies on the registry are indexed under Intestinal Obstruction; 16 are open to participants now.

Browse Intestinal Obstruction studies →

Open to participants now

2 of the 29 studies in Intestinal Obstruction with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Intestinal Obstruction studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; 3 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Intestinal Obstruction with a site in United States, or all of them as a file.
02

Study summary

This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome extended-release injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.

Read the detailed description

This is a phase 4, prospective, sequential, open-label study designed to evaluate the efficacy, safety, and health economic benefits of intraoperative local wound infiltration with EXPAREL (bupivacaine liposome extended-release injectable suspension), compared with postsurgical administration of standardized intravenous (IV) morphine sulfate, for postsurgical analgesia in adult patients undergoing open colectomy with general anesthesia.

03

Conditions studied

  • Bowel Obstruction

Keywords

  • open colectomy
  • colectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, 18 years of age or older.
  • Patients scheduled to undergo open segmental colectomy with planned primary anastamosis, as defined by cecectomy, right hemicolectomy, resection of transverse colon, left hemicolectomy, or sigmoidectomy.
  • Ability to provide , adhere to study visit schedule, and complete all assessments.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of or idiosyncratic reactions or intolerance to any local anesthetic, opioid, or propofol.
  • Patients who abuse alcohol or other drug substance.
  • Patients with severe hepatic impairment.
  • Patients currently pregnant or who may become pregnant during the course of the study.
  • Patients with any psychiatric, psychological, or other condition that the Investigator feels may make the patient an inappropriate candidate for this clinical study.
  • Patients who have participated in a EXPAREL study within the last 30 days.
  • Patients who have received an drug within 30 days prior to study drug administration, or planned administration of another investigational product or procedure during the patient's participation in this study.
  • Patients who undergo any concurrent surgical procedure during the ileostomy reversal surgery.

In addition, the patient will be ineligible if he/she meets the following criteria during surgery:

  • Patients with unplanned multiple segmental resections or large intestine.
  • Patients who have unplanned, temporary or permanent colostomies, ileostomies, or the like placed.
  • Patients who receive intraoperative administration of opioids (other than fentanyl or analogs) or an other analgesic, local anesthetics, or anti-inflammatory agents.
  • Patients who receive Entereg(R).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Active comparator
    IV morphine sulfate

    morphine sulfate (or Sponsor-approved equivalent)

    Drug: IV morphine sulfate

  • Experimental
    EXPAREL

    EXPAREL (bupivacaine liposome injectable suspension)

    Drug: EXPAREL (bupivacaine liposome injectable suspension)

Interventions

  • Patients in this group will receive IV morphine sulfate via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour.

    Also known as: morphine sulfate (or Sponsor-approved equivalent)

  • Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac, a non-steroidal anti-inflammatory drug (NSAID), may be substituted per the site's standard of care. All patients will be offered rescue analgesia, as needed.

    Also known as: bupivacaine free base

06

What researchers measure

Primary outcomes

  1. Total Opioid Burden

    Total opioid consumed (IV and PO) postsurgically until the hospital discharge order is written or through Day 30, whichever is sooner.

    Time frame: Wound closure to time hospital discharge order written or Day 30, whichever is sooner

  2. Health Economic Benefits

    1. Total cost of hospitalization until the time hospital discharge order is written or through Day 30, whichever is sooner. 2. Length of stay (LOS), recorded in hours, defined as the time of completion of the wound closure until the hospital discharge order is written or through Day 30, whichever is sooner.

    Time frame: Wound closure to Day 30

Secondary outcomes

  1. Incidence of Opioid-related Adverse Events and Patient Satisfaction With Postsurgical Analgesia.

    1. Incidence of opioid-related adverse events defined as somnolence, respiratory depression, hypoventilation, hypoxia, dry mouth, nausea, vomiting, constipation, sedation, confusion, pruritus, urinary retention, and postoperative ileus. 2. Responses to one question pertaining to patient satisfaction with postsurgical analgesia and four questions pertaining to postsurgical recovery following hospital discharge.

    Time frame: Wound closure to time hospital discharge order written or Day 30, whichever is sooner.

07

Results

Posted Mar 6, 2014

Participant flow

Participant flow — Overall Study
MilestoneIV Morphine SulfateEXPAREL
Started50
Completed50
Not completed00

Outcome measures

PrimaryTotal Opioid Burden

Total opioid consumed (IV and PO) postsurgically until the hospital discharge order is written or through Day 30, whichever is sooner.

Time frame:
Wound closure to time hospital discharge order written or Day 30, whichever is sooner

No measurements were reported for this outcome.

PrimaryHealth Economic Benefits

1. Total cost of hospitalization until the time hospital discharge order is written or through Day 30, whichever is sooner. 2. Length of stay (LOS), recorded in hours, defined as the time of completion of the wound closure until the hospital discharge order is written or through Day 30, whichever is sooner.

Time frame:
Wound closure to Day 30

No measurements were reported for this outcome.

SecondaryIncidence of Opioid-related Adverse Events and Patient Satisfaction With Postsurgical Analgesia.

1. Incidence of opioid-related adverse events defined as somnolence, respiratory depression, hypoventilation, hypoxia, dry mouth, nausea, vomiting, constipation, sedation, confusion, pruritus, urinary retention, and postoperative ileus. 2. Responses to one question pertaining to patient satisfaction with postsurgical analgesia and four questions pertaining to postsurgical recovery following hospital discharge.

Time frame:
Wound closure to time hospital discharge order written or Day 30, whichever is sooner.

No measurements were reported for this outcome.

Adverse events

Collected over 30 days post surgery. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IV Morphine Sulfate—2/5 (40%)5/5 (100%)
EXPAREL———
Most frequent serious events
Most frequent serious events
EventIV Morphine SulfateEXPAREL
Wound infectionInfections and infestations1/5—
Mesenteric vein thrombosisGastrointestinal disorders1/5—
Postoperative ileusInjury, poisoning and procedural complications1/5—
Most frequent other events
Showing 10 of 16
Most frequent other events
EventIV Morphine SulfateEXPAREL
TachycardiaCardiac disorders3/5—
NauseaGastrointestinal disorders3/5—
Urine output decreasedInvestigations2/5—
LeukocytosisBlood and lymphatic system disorders2/5—
HypotensionVascular disorders2/5—
VomitingGastrointestinal disorders2/5—
HypocalcemiaMetabolism and nutrition disorders2/5—
HyponatremiaMetabolism and nutrition disorders2/5—
AnemiaBlood and lymphatic system disorders1/5—
HyperthermiaGeneral disorders1/5—

Baseline characteristics

Age, Continuous
Age, Continuous(years)IV Morphine SulfateEXPARELTotal
Mean53.6 ± 13.76—53.6 ± 13.76
Age, Categorical
Age, Categorical(participants)IV Morphine SulfateEXPARELTotal
<=18 years0—0
Between 18 and 65 years4—4
>=65 years1—1
Gender
Gender(participants)IV Morphine SulfateEXPARELTotal
Female3—3
Male2—2
Region of Enrollment
Region of Enrollment(participants)IV Morphine SulfateEXPARELTotal
United States5—5
08

Study locations

1 site
  • University of Miami, Dept of Anesthesiology
    Miami, Florida 33136, United States
09

References and documents

Publications

  • Cohen SM, Vogel JD, Marcet JE, Candiotti KA. Liposome bupivacaine for improvement in economic outcomes and opioid burden in GI surgery: IMPROVE Study pooled analysis. J Pain Res. 2014 Jun 24;7:359-66. doi: 10.2147/JPR.S63764. eCollection 2014. PubMed 25018650 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2011
First posted
Jan 10, 2012
Start
May 2012
Primary completionActual
Jul 2012
CompletionActual
Jul 2012
Results first posted
Mar 6, 2014
Last update
Mar 6, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01507233
Collaborators
Registrat-Mapi
Responsible party
Sponsor
First posted
Jan 10, 2012
Start date
May 2012
Primary completion
Jul 2012
Completion
Jul 2012
Results posted
Mar 6, 2014
Last update
Mar 6, 2014

Study contacts

Keith Candiotti, M.D.
principal investigator · University of Miami

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal Bupivacaine

Start the discussion